CITIUS ONCOLOGY, INC. Logo

CITIUS ONCOLOGY, INC.

Biopharmaceutical company developing and commercializing targeted oncology therapies.

CTOR | US

Overview

Corporate Details

ISIN(s):
US17331Y1091
LEI:
Country:
United States of America
Address:
11 COMMERCE DRIVE, 7016 CRANFORD

Description

Citius Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative targeted oncology therapies. Its lead product, LYMPHIR™ (denileukin diftitox-cxdl), is a targeted immune therapy approved by the U.S. Food and Drug Administration (FDA) in August 2024. LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company's strategy involves expediting development pathways for treatments with reduced clinical risks and securing competitive advantages through intellectual property and regulatory exclusivity. Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, Inc.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all CITIUS ONCOLOGY, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CITIUS ONCOLOGY, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CITIUS ONCOLOGY, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.